Coherus Biosciences Inc

NASDAQ:CHRS   1:54:15 PM EDT
12.82
-0.26 (-1.99%)
Products

FDA Approves Coherus' Cimerli, First Product Sales Expected In October 2022

Published: 08/02/2022 23:22 GMT
Coherus Biosciences Inc (CHRS) - FDA Approves Coherus’ Cimerli™ (ranibizumab-eqrn) As the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, With 12 Months of Interchangeability Exclusivity.
Coherus Biosciences Inc- First Cimerli™ Product Sales Expected in October 2022.